Date: 2012-01-23
Type of information: Development agreement
Compound: platform for high-density cell cultivation
Company: Sartorius Stedim Biotech (Germany) Refine Technology (USA)
Therapeutic area:
Type agreement: collaboration
development
Action mechanism:
Disease:
Details: Sartorius Stedim Biotech and Refine Technology will be collaborating on the development of a robust platform for high-density cell cultivation. This platform will enable fast, easy connection of the ATF System to SSB’s field-proven single-use BIOSTAT® bioreactors. This joint development project proactively responds to the current market demand for more effective connectivity between equipment from different suppliers to enable development of efficient, streamlined systems.
As a first step, Sartorius Stedim Biotech and Refine are now providing users with initial application and protocol guidance for connecting the SSB single-use and reusable bioreactors and Refine’s ATF System. In the future, both companies will work closely together, along with customers, to provide improved automation and process operation.
Financial terms:
Latest news:
